Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New muscle relaxant injection passes first safety check in healthy volunteers

NCT ID NCT06932315

Knowledge-focused Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new injection called HRS-9190 in 53 healthy adults aged 18 to 45. The main goal was to check safety and how the body processes different doses. No treatment for any condition was given; this was purely to gather safety and dosing information for future studies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HRS-9190 injection

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

53 people

The number who actually took part.

Started

Apr 2025

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Healthy male and female subjects aged 18 to 45 years (inclusive). 2. Subjects must have no pregnancy plans for the next three months and agree to use highly effective contraception throughout the trial period. 3. Capable of understanding the study requirements and willing to provide written informed consent. Exclusion Criteria: 1. Presence of any clinically significant condition that could interfere with trial participation. 2. History or current diagnosis of neuromuscular disorders. 3. Major surgery within 6 months pre-screening, or planned surgical procedures during the study. 4. Vaccination received within 1 month prior to screening or planned vaccination during the trial period. 5. Participation in another investigational drug trial within 3 months pre-screening. 6. Clinically significant abnormalities in screening/baseline physical examinations. 7. Positive alcohol breath test at screening. 8. Pregnancy or lactation status (for female subjects). 9. Investigator-determined unsuitability for study participation or predicted protocol non-compliance.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Skeletal muscle relaxation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Skeletal muscle relaxation

Contacts and locations

Locations

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, 410013, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.